16 research outputs found
18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO
Molecular imaging receives increased attention for selecting patients who will benefit from targeted anticancer therapies. Neo-ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) enrolled 455 women with invasive human epidermal growth factor receptor 2 (HER2)-positive breast cancer and compared rates of pathologic complete response (pCR) to neoadjuvant lapatinib, trastuzumab, and their combination. Each anti-HER2 therapy was given alone for 6 wk, followed by 12 wk of the same therapy plus weekly paclitaxel. The early metabolic effects of the anti-HER2 therapies on the primary tumors and their predictive values for pCR were assessed in a subset of patients. Methods: eighty-six patients underwent (18)F-FDG PET/CT at baseline and weeks 2 and 6 of anti-HER2 treatment. An imaging core laboratory provided central validation, and 2 independent reviewers, masked to assigned treatment arm and clinical outcomes, performed consensus (18)F-FDG PET/CT readings. Maximum standardized uptake value (SUVmax) reductions from baseline were used to measure metabolic response. Results: seventy-seven of the 86 enrolled patients presented an evaluable baseline (18)F-FDG PET/CT scan; of these, 68 and 66 were evaluable at weeks 2 and 6, respectively. Metabolic responses in the primary tumors were evident after 2 wk of targeted therapy and correlated highly with metabolic responses at week 6 (R(2) = 0.81). pCRs were associated with greater SUVmax reductions at both time points. Mean SUVmax reductions for pCR and non-pCR, respectively, were 54.3% versus 32.8% at week 2 (P = 0.02) and 61.5% versus 34.1% at week 6 (P = 0.02). (18)F-FDG PET/CT metabolic response rates at weeks 2 and 6 were 71.6% and 60%, respectively using European Organization for Research and Treatment of Cancer criteria; pCR rates were twice as high for (18)F-FDG PET/CT responders than nonresponders (week 2: 42% vs. 21%, P = 0.12; week 6: 44% vs. 19%, P = 0.05). Conclusion: early metabolic assessment using (18)F-FDG PET/CT can identify patients with an increased likelihood of pCR after neoadjuvant trastuzumab, lapatinib, or their combination when given with chemotherapy
De l'onco-gériatrie générale à la prise en charge spécifique du cancer du cÎlon-rectum chez la personne ùgée
CLERMONT FD-BCIU-Santé (631132104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF
Trastuzumab et cardiotoxicité
CLERMONT FD-BCIU-Santé (631132104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF
Cancer du sein et grossesse
CLERMONT FD-BCIU-Santé (631132104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF
Traitement de consolidation ou de maintenance dans le cancer épithélial de l'ovaire de stade avancé (expérience du Centre Jean Perrin)
AprĂšs une revue de la littĂ©rature des traitements de consolidation ou de maintenance Ă©valuĂ©s dans le cancer Ă©pithĂ©lial de l'ovaire de stade avancĂ©, l'auteur rapporte les modalitĂ©s mises en Ćuvre au Centre de Lutte contre le Cancer Jean Perrin de Clermont-Ferrand. Une 1Ăšre Ă©tude rĂ©trospective reprend les donnĂ©es de 77 patientes traitĂ©s, en situation de consolidation, par chimiothĂ©rapie intensive avec support de cellules souches hĂ©matopoĂŻĂ©tiques. avec un recul mĂ©dian de 189 mois, les mĂ©dianes de survie sans rechute et de survie globale sont respectivement de 31 et 55 mois aprĂšs le diagnostic. Cette option thĂ©rapeutique est donc tout Ă fait rĂ©alisable avec de bons rĂ©sultats mais chez des patientes trĂšs sĂ©lectionnĂ©es. La 2Ăšme Ă©tude rĂ©trospective s'intĂ©resse Ă l'apport de 3 cures de chimiothĂ©rapie supplĂ©mentaires aprĂšs un traitement d'induction par chirurgie et six cures d'une association paclitaxel et carboplatine. Elle regroupe 125 patientes prĂ©sentant un cancer de l'ovaire de stade IIIC ou IV. La prolongation du traitement ne semble pas apporter de bĂ©nĂ©fice avec une survie globale identique dans les 2 bras. Par ailleurs, la dĂ©croissance du marqueur sĂ©rique CA 125 semble un facteur prĂ©dictif indĂ©pendant de rĂ©ponse au traitement. Enfin, les donnĂ©es prospectives de 16 patientes randomisĂ©es dans un essai de phase III comparant un traitement de maintenance par erlotinib Ă une simple surveillance ont Ă©tĂ© analysĂ©es. Les survies sans rĂ©cidives sont Ă©quivalentes dans les 2 groupes.CLERMONT FD-BCIU-SantĂ© (631132104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF
Optimisation du traitement médical du cancer de la prostate hormono-résistant
CLERMONT FD-BCIU-Santé (631132104) / SudocPARIS-BIUP (751062107) / SudocSudocFranceF
Optimisation du traitement médical du cancer de la prostate hormono-résistant
CLERMONT FD-BCIU-Santé (631132104) / SudocPARIS-BIUP (751062107) / SudocSudocFranceF
The CMS Magnet Commissioning and the Development of an Improved CMS Conductor Suitable for Future Proposals
The success of the CMS Magnet commissioning has clearly shown the reliability of the conceptual choices for the cold mass. The reinforced conductor and the multi layer winding open the path for the conception of Large Magnet for HEP of the next generation. The paper will report about the basic results of the test campaign and then, after some critical considerations about the choices made for the CMS coil construction, possible improvements for the conductor construction are outlined. The main goal being to preserve long term RRR, and thus stability, of the insert and simplify the welding process to join the reinforcement alloy to the insert
Is It Important to Adapt Neoadjuvant Chemotherapy to the Visible Clinical Response? An Open Randomized Phase II Study Comparing ResponseâGuided and Standard Treatments in HER2âNegative Operable Breast Cancer
18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.
Molecular imaging receives increased attention for selecting patients who will benefit from targeted anticancer therapies. Neo-ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) enrolled 455 women with invasive human epidermal growth factor receptor 2 (HER2)-positive breast cancer and compared rates of pathologic complete response (pCR) to neoadjuvant lapatinib, trastuzumab, and their combination. Each anti-HER2 therapy was given alone for 6 wk, followed by 12 wk of the same therapy plus weekly paclitaxel. The early metabolic effects of the anti-HER2 therapies on the primary tumors and their predictive values for pCR were assessed in a subset of patients.SCOPUS: ar.jinfo:eu-repo/semantics/publishe